Although most associations between routine blood tests and AD biomarkers in preclinical AD did not reach statistical significance, consistent trends were observed, supporting the value of these measures as candidates for further investigation.
← all excerpts
Development and validation of an interpretable clinical scoring model to monitor the progression of preclinical Alzheimer's disease.
1
—
—